Related Experiment Video

Updated: Aug 18, 2026

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen
19:44

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen

Published on: May 30, 2012

Anticancer drug resistance and inhibition of apoptosis

B Desoize1

  • 1GIBSA, Institut Godinot, Reims, France.

Anticancer Research
|November 1, 1994
PubMed

Insights

Bcl-2 protein inhibits apoptosis, leading to chemotherapy resistance in cancer. Understanding and targeting Bcl-2 expression is crucial for developing effective cancer treatments.

Area of Science:

  • Oncology
  • Molecular Biology

Background:

  • Apoptosis, or programmed cell death, is vital for understanding and treating cancer.
  • Inhibitors of apoptosis, such as Bcl-2, confer resistance to chemotherapy and irradiation.
  • Bcl-2 overexpression correlates with poor prognosis in various cancers.

Purpose of the Study:

  • To explore the role of Bcl-2 in apoptosis and cancer.
  • To investigate the clinical significance of Bcl-2 expression.
  • To evaluate Bcl-2 antisense oligonucleotides as a therapeutic strategy.

Main Methods:

  • Review of existing literature on Bcl-2 and apoptosis.
  • Analysis of clinical data correlating Bcl-2 expression with cancer prognosis.
  • Examination of the molecular mechanisms of Bcl-2's antioxidant and anti-apoptotic functions.

Main Results:

  • Bcl-2 protein, located in mitochondria, nuclear envelope, and endoplasmic reticulum, acts as an antioxidant.
  • Overexpression of Bcl-2 reduces cancer cell sensitivity to cytotoxic drugs, while underexpression increases sensitivity.
  • Bcl-2 antisense oligonucleotides demonstrated the ability to reverse apoptosis inhibition.

Conclusions:

  • Bcl-2 is a key regulator of apoptosis and a significant factor in cancer drug resistance.
  • Targeting Bcl-2 expression holds promise for novel cancer therapeutic strategies.
  • Future cancer treatments must consider Bcl-2 expression levels for personalized therapy.

More Related Videos

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo09:19

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Published on: February 6, 2015

Establishing Cell Lines Overexpressing DR3 to Assess the Apoptotic Response to Anti-mitotic Therapeutics12:28

Establishing Cell Lines Overexpressing DR3 to Assess the Apoptotic Response to Anti-mitotic Therapeutics

Published on: January 11, 2019

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...